Opella, Sanofi

Sanofi in 'exclusive negotiations' to sell 50% stake in €16B consumer health unit Opella
Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC) business unit,
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
By Dominique Patton PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R
Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare
Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale
Sanofi entered into exclusive talks to sell its consumer-healthcare business Opella to Clayton Dubilier & Rice in a deal that values the business as a whole at $17.4 billion, including debt.
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.
Sanofi Enters Exclusive Talks to Sell 50% Stake in Opella to CD&R
Sanofis Exclusive Negotiations with Clayton Dubilier Rice Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division,
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...
GlobalData on MSN4d
Sanofi’s $17bn sale of Opella to US investors advances following government deal
A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...
Sanofi’s Strategic Moves and Financial Prospects Drive Buy Rating
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...
STAT10d
Pharmalittle: We’re reading about generic weight loss drugs, anxiety over a Sanofi deal, and more
India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...
2minutemedicine.com3d
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
The Pharma Letter14h
Sanofi outpaces expectations in third quarter 2024
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
Zawya3d
Sanofi and NUPCO sign the offtake agreement
and packaging of Sanofi’s SoloStar insulin pens and advanced insulin products. This strategic partnership reinforces our ...
Morningstar8d
Sanofi SA ADR SNY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance4d
Trending tickers: Boeing, Sanofi, SAP, Nokia and Tata Consumer Products
US planemaker Boeing is heading into a busy week, with investors watching developments closely around its costly labour strike, as well as its latest quarterly results. More than 33,000 unionised ...